Blood Test Determines Reduced and Oxidized Glutathione
|
By LabMedica International staff writers Posted on 31 Jul 2013 |

Image: API 3000 triple-quadrupole mass spectrometer (Photo courtesy of Applied Biosystems).
Diminished levels of glutathione (γ-glutamylcysteinylglycine, GSH) and the ratio of GSH to glutathione disulfide (GSSG) can serve as important indicators of oxidative stress and disease risk.
A simple and sensitive liquid chromatography-tandem mass spectrometry (LC–MS/MS) method for measuring whole blood GSH and GSSG has been developed and can easily be implemented in clinical laboratories.
Scientists at Stanford University School of Medicine (CA, USA) developed an approach that minimizes preanalytical variability through a one-step procedure of deproteinization and derivatization that prevents artifactual oxidation of GSH, and is easily adapted to the clinical setting without requiring excessive constraints on sample handling or storage. The team used anonymous, residual blood samples from 59 healthy individuals, 31 males, and 28 females, with an age range 1 to 87 years, with a mean of 25 years.
Compounds were separated by liquid chromatography using a Hypercarb column (Thermo Scientific; Waltham, MA, USA) at room temperature. The GSH and GSSG ions and fragments were detected using the API 3000 triple-quadrupole mass spectrometer (Perkin-Elmer; Waltham, MA, USA). The final concentrations of GSH and GSSG were expressed in units of μmol/L of whole blood.
The lower limits of detection (LLOD) were 0.4 μM for GSH and 0.1 μM for GSSG and the lower limits of quantitation (LLOQ) were 1.5 μM for GSH and 0.1 μM for GSSG. There was excellent linearity for both GSH and GSSG over the ranges of physiologic normal, with inter- and intra-assay coefficient of variation of 3.1% to 4.3% and accuracy between 95% and 101%. Derivatized samples are stable for at least three years when stored at -80 °C and underivatized samples for at least 24 hours at either 4 °C or room temperature. As a group, the mean concentration ± standard deviation for GSH was 900 ± 140 μM, GSSG 1.17 ± 0.43 μM, and GSH/GSSG ratio was 880 ± 370.
The authors concluded that their LC–MS/MS method minimizes preanalytic variability through a one-step procedure of deproteinization and derivatization, and chromatographic conditions that eliminate ion suppression and increase precision and sensitivity. Additional advantages included the small sample requirement, simple and rapid preanalytical processing, and wide automation possibilities, which makes this method ideal for routine and large-scale clinical testing. The study was published on June 15, 2013, in the Journal of Chromatography B.
Related Links:
Stanford University School of Medicine
Thermo Scientific
Perkin-Elmer
A simple and sensitive liquid chromatography-tandem mass spectrometry (LC–MS/MS) method for measuring whole blood GSH and GSSG has been developed and can easily be implemented in clinical laboratories.
Scientists at Stanford University School of Medicine (CA, USA) developed an approach that minimizes preanalytical variability through a one-step procedure of deproteinization and derivatization that prevents artifactual oxidation of GSH, and is easily adapted to the clinical setting without requiring excessive constraints on sample handling or storage. The team used anonymous, residual blood samples from 59 healthy individuals, 31 males, and 28 females, with an age range 1 to 87 years, with a mean of 25 years.
Compounds were separated by liquid chromatography using a Hypercarb column (Thermo Scientific; Waltham, MA, USA) at room temperature. The GSH and GSSG ions and fragments were detected using the API 3000 triple-quadrupole mass spectrometer (Perkin-Elmer; Waltham, MA, USA). The final concentrations of GSH and GSSG were expressed in units of μmol/L of whole blood.
The lower limits of detection (LLOD) were 0.4 μM for GSH and 0.1 μM for GSSG and the lower limits of quantitation (LLOQ) were 1.5 μM for GSH and 0.1 μM for GSSG. There was excellent linearity for both GSH and GSSG over the ranges of physiologic normal, with inter- and intra-assay coefficient of variation of 3.1% to 4.3% and accuracy between 95% and 101%. Derivatized samples are stable for at least three years when stored at -80 °C and underivatized samples for at least 24 hours at either 4 °C or room temperature. As a group, the mean concentration ± standard deviation for GSH was 900 ± 140 μM, GSSG 1.17 ± 0.43 μM, and GSH/GSSG ratio was 880 ± 370.
The authors concluded that their LC–MS/MS method minimizes preanalytic variability through a one-step procedure of deproteinization and derivatization, and chromatographic conditions that eliminate ion suppression and increase precision and sensitivity. Additional advantages included the small sample requirement, simple and rapid preanalytical processing, and wide automation possibilities, which makes this method ideal for routine and large-scale clinical testing. The study was published on June 15, 2013, in the Journal of Chromatography B.
Related Links:
Stanford University School of Medicine
Thermo Scientific
Perkin-Elmer
Latest Clinical Chem. News
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
- Routine Blood Markers Predict Heart Failure Risk in Prediabetes
- AI Model Enables Personalized Glucose Predictions for Type 1 Diabetes
- AI-Powered Blood Test Distinguishes Deadly Cardiac Events
- AI Sensor Detects Neurological Disorders Using Single Saliva Drop
- Blood Test Tracks Transplant Health Using Donor DNA
- New Blood Test Index Offers Earlier Detection of Liver Scarring
- Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
- Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care
- Existing Hospital Analyzers Can Identify Fake Liquid Medical Products
Channels
Molecular Diagnostics
view channel
New Respiratory Panel Expands Pathogen Detection to 25 Targets
Respiratory infections often present with overlapping symptoms, complicating differential diagnosis in acute and community settings. The stakes are higher for older adults, young children, and people with... Read more
Simple Nasal Swab May Reveal Early Signs of Alzheimer’s Disease
Alzheimer’s disease affects millions worldwide but remains difficult to detect at its earliest, pre-symptomatic stage. Clinicians need tools that can identify biological changes before cognitive symptoms... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
Early identification of treatment response and relapse remains a major challenge in solid tumors, where minimal residual disease is difficult to detect with routine imaging and blood tests.... Read moreMicrobiology
view channel
Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
Accurate and rapid identification of bacterial infections remains challenging in acute care, where delays can hinder timely, targeted therapy. Infectious diseases are a major cause of mortality worldwide,... Read more
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read more
AI-Powered Tool to Transform Dermatopathology Workflow
Skin cancer accounts for the largest number of cancer diagnoses in the United States, placing sustained pressure on pathology services. Diagnostic interpretation can be variable for challenging melanocytic... Read moreTechnology
view channel
Online Tool Supports Family Screening for Inherited Cancer Risk
Genetic test results in oncology often have implications for relatives who may share inherited cancer risk. Many health systems lack structured processes to help patients alert family members, limiting... Read more
Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
Pneumonia is commonly confirmed with chest X-rays or laboratory assays that can take hours, delaying clinical decisions in acute and outpatient settings. Breath-based diagnostics promise faster answers... Read moreIndustry
view channel
Integrated DNA Technologies Expands into Clinical Diagnostics
Integrated DNA Technologies (IDT; Coralville, Iowa, USA) has announced the launch of Archer FUSIONPlex-HT Dx and VARIANTPlex-HT Dx. This launch marks the company’s first in vitro diagnostic (IVD) offerings... Read more




.jpg)



